Be the first to know

Never miss an update from CSL. Did you know that during reporting season, the announcements from ASX:CSL often move the market?

CSL (ASX:CSL) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow CSL

CSL (CSL)

AU ASX:CSL (137.9B)

297.38
-5.53 (-1.86%)
0:03am AEDT
LOADING
Loading price chart..

Summary

Current Price: $297.38
52w High/Low: $242.67 - 342.75
Market Cap: 137.9B
Price/Earnings: 44.88
Dividend Yield: 0.97%
Volume/Average: 1.9M - $933
CSL (ASX:CSL) Company Logo

Listed in 1994

Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.
CSL (ASX:CSL) Company Logo

Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.

Annual Reports

Annual Report to shareholders Sep 3rd 2020
2020
(5.8mb)
CSL Annual Report 2018/19 Sep 5th 2019
2019
(6.8mb)
CSL Annual Report to shareholders Sep 13th 2018
2018
(5.8mb)
Annual Report to Shareholders Sep 14th 2017
2017
(5.8mb)
Annual Report to shareholders Sep 8th 2016
2016
(5.5mb)
Annual Report to shareholders Sep 11th 2015
2015
(4.3mb)

Dividend History

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Dividend Yield
0.4%
 
1.0%
 
 
Industry Avg
CSL

ATTRACTIVE: CSL's dividend yield of 1.0% exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Implied Growth
29.5%
 
7.8%
 
 
Industry Avg
CSL

ATTRACTIVE: CSL exhibits an implied growth ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. CSL calculation: 10% - ($6.72 / $297.38) = 7.7% more
Price / Book
6.7
 
14.5
 
 
Industry Avg
CSL

UNATTRACTIVE: CSL exhibits a price/book ratio which exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Price / Earnings
28.8
 
45.1
 
 
Industry Avg
CSL

UNATTRACTIVE: CSL's price/earnings ratio of 45.1 exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Price / Sales
13.3
 
10.4
 
 
Industry Avg
CSL

ATTRACTIVE: CSL exhibits a price/sales ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more

Company News

Why Platinum Asset's healthcare fund doesn't own CSL (ASX:CSL) shares
November 30th, 2020 - Motley Fool

Advantage Moderna Despite CSL’s strong performance history and major blue chip status, Platinum Asset Management’s unlisted international healthcare fund doesn’t own any shares. Platinum’s data reports that the fund returned 25.7% net of fees over...

Why the CSL (ASX:CSL) share price may be in danger
November 29th, 2020

The CSL Limited (ASX:CSL) share price could be in danger, if these new vaccines become the new normal way of doing things. The information in this article contains general financial advice only and is authorised by The Rask Group Pty Ltd (ABN: 36 ...

Everything you need to know about the Pushpay (ASX:PPH) share split
November 23rd, 2020 - Motley Fool

Why is Pushpay splitting its shares? Traditionally, share splits have been a way to make share ownership more accessible for smaller investors like you and me. That’s because companies with high share prices can be out of reach for investors if th...

ASX 200 to rise after positive AstraZeneca COVID-19 vaccine news
November 23rd, 2020 - Motley Fool

What is the new vaccine candidate? Overnight British pharmaceutical giant AstraZeneca revealed that data from an interim analysis of clinical trials showed that its vaccine, AZD1222, had an average efficacy of 70% in protecting against COVID-19. T...

Fundie names 5 ASX shares with good growth prospects
November 23rd, 2020 - Motley Fool

Clime is bullish about the following ASX shares: Macquarie Group Ltd (ASX: MQG) Macquarie is a global investment bank, it earns around a third of its net income in Australia. Clime said that the highly stimulatory Australian federal budget and ...

ASX 200 Weekly Wrap: ASX continues to climb, despite outage
November 22nd, 2020 - Motley Fool

ASX shutdown Yes, the ASX was closed for the majority of trading on Monday, the first time the exchange has had to shut unexpectedly in years. In fact, after trading opened at 10am on Monday, investors were only treated to approximately 24 minutes...

What would it take for the ASX 200 to hit 7,000 again?
November 20th, 2020 - Motley Fool

How do banks fit into the ASX 200? The ASX 200 is a market capitalisation-weighted index. This means that the largest companies (by market cap) within the index have the most influence on the index. To illustrate, the ASX 200’s largest holding is ...

5 things to watch on the ASX 200 on Friday
November 19th, 2020 - Motley Fool

ASX 200 expected to push higher. The Australian share market could end the week on a positive note. According to the latest SPI futures, the ASX 200 is expected to push 17 points or 0.25% higher at the open. In late trade on Wall Street, the Dow J...